Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

NCT07373990 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

418

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancer

Interventions

DRUG: tislelizumab
DRUG: tislelizumab
DRUG: Gemcitabine + cisplatin (GP)
DRUG: Cisplatin (100mg/m2)
RADIATION: intensity-modulated radiotherapy

Sponsor

Sun Yat-sen University